What is Galera Therapeutics, Inc.'s earnings per share (EPS)?

Galera Therapeutics, Inc. (GRTX) reported diluted earnings per share of $0.64 for fiscal year 2025. This represents a 288.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Galera Therapeutics, Inc. Financials

GRTX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Galera Therapeutics, Inc. (GRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GRTX FY2025 2026-05-14

FY2025 reflects a balance-sheet reset and sharp operating downsizing, not a revenue-driven improvement in the business model.

The crucial change is that equity flipped from negative to positive in FY2025 because total liabilities collapsed from $158.1M to $3.2M. With operating cash flow still negative at -$6.0M, solvency improved mainly through a capital-structure reset rather than through self-funding operations.

The drop in operating loss from -$49.3M in FY2023 to -$2.5M in FY2025 came alongside steep cuts to R&D and SG&A, which signals a much smaller organization rather than a business that found commercial scale. The cost base was taken down faster than any operating engine was built up.

Capex stayed negligible across the recent valid years, so cash burn was not coming from equipment or facility build-out. FY2025 ended with $6.4M of cash and only $645K of current liabilities, a liquid near-term posture that mainly buys time while the company remains cash-consuming.

Financial Health Signals

Financial Profile 31/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Galera Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Galera Therapeutics, Inc. carries a low D/E ratio of 0.81, meaning only $0.81 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 11.00, Galera Therapeutics, Inc. holds $11.00 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$2.5M

YoY+87.4%

Galera Therapeutics, Inc.'s EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 87.4% from the prior year.

Net Income

N/A

EPS (Diluted)

$0.64

YoY+288.2%

Galera Therapeutics, Inc. earned $0.64 per diluted share (EPS) in fiscal year 2025. This represents an increase of 288.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$6.4M

YoY-23.1%

5Y CAGR-16.7%

Galera Therapeutics, Inc. held $6.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

75M

YoY+38.7%

5Y CAGR+24.8%

Galera Therapeutics, Inc. had 75M shares outstanding in fiscal year 2025. This represents an increase of 38.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$349K

YoY-88.9%

5Y CAGR-63.6%

Galera Therapeutics, Inc. invested $349K in research and development in fiscal year 2025. This represents a decrease of 88.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GRTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$349K-88.9%	$3.2M-86.9%	$24.1M-22.2%	$31.0M-40.8%	$52.4M-4.4%	$54.8M
SG&A Expenses	$5.7M-48.3%	$11.0M-51.8%	$22.8M+13.0%	$20.2M-3.5%	$21.0M+33.4%	$15.7M
Operating Income	-$2.5M+87.4%	-$20.2M+59.1%	-$49.3M+3.8%	-$51.2M+30.2%	-$73.4M-4.0%	-$70.6M
Interest Expense	$0	$0-100.0%	$11.4M-1.4%	$11.6M+60.8%	$7.2M+47.4%	$4.9M
Income Tax	$0+100.0%	-$203K	$0-100.0%	$70K	$0+100.0%	-$16K
Net Income	N/A	-$19.0M+67.9%	-$59.1M+5.0%	-$62.2M+22.7%	-$80.5M-8.5%	-$74.2M
EPS (Diluted)	$0.64+288.2%	$-0.34+74.4%	$-1.33+42.2%	$-2.30+26.3%	$-3.12	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15K	N/A	$130K+54.8%	$84K-9.7%	$93K	N/A	$305K-78.7%	$1.4M
SG&A Expenses	$1.6M	N/A	$1.3M+24.3%	$1.1M-43.8%	$1.9M	N/A	$3.4M+23.7%	$2.8M
Operating Income	-$1.7M	N/A	-$1.4M-26.5%	-$1.1M+42.2%	-$2.0M	N/A	-$5.9M-40.4%	-$4.2M
Interest Expense	$0	N/A	$0	N/A	$0	N/A	$0	$0
Income Tax	N/A	N/A	$0	N/A	N/A	N/A	-$203K	N/A
Net Income	-$1.6M	N/A	-$1.4M-29.1%	-$1.1M+32.5%	-$1.6M	N/A	-$5.6M-37.3%	-$4.1M
EPS (Diluted)	$-0.01	N/A	$-0.01	$0.00+100.0%	$-0.01	N/A	$-0.10-42.9%	$-0.07

GRTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.2M-28.8%	$10.1M-61.4%	$26.1M-40.6%	$44.0M-47.1%	$83.3M-0.9%	$84.1M
Current Assets	$7.1M-29.1%	$10.0M-53.8%	$21.6M-43.9%	$38.5M-50.2%	$77.4M-0.7%	$77.9M
Cash & Equivalents	$6.4M-23.1%	$8.3M-54.6%	$18.3M+328.0%	$4.3M-78.5%	$19.9M+25.1%	$15.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$0-100.0%	$881K0.0%	$881K0.0%	$881K0.0%	$881K
Total Liabilities	$3.2M-98.0%	$158.1M+0.5%	$157.3M+2.7%	$153.2M+8.4%	$141.3M+81.2%	$78.0M
Current Liabilities	$645K-61.3%	$1.7M-66.4%	$5.0M-62.9%	$13.4M+3.4%	$12.9M-7.4%	$14.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.0M+102.7%	-$148.0M-12.8%	-$131.2M-20.2%	-$109.2M-88.2%	-$58.0M-1048.1%	$6.1M
Retained Earnings	-$307.3M+32.7%	-$456.4M-4.3%	-$437.4M-15.6%	-$378.3M-19.7%	-$316.1M-34.2%	-$235.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$6.2M-14.3%	$7.2M+43.9%	$5.0M-17.3%	$6.0M-21.1%	$7.7M-24.2%	$10.1M+13.5%	$8.9M-45.7%	$16.4M
Current Assets	$6.1M-14.5%	$7.1M+44.8%	$4.9M-17.6%	$5.9M-21.3%	$7.6M-24.4%	$10.0M+12.4%	$8.9M-25.6%	$12.0M
Cash & Equivalents	$5.5M-13.7%	$6.4M+42.5%	$4.5M-14.5%	$5.2M-21.8%	$6.7M-19.3%	$8.3M-2.0%	$8.5M-21.3%	$10.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$881K
Total Liabilities	$5.4M+68.7%	$3.2M-97.9%	$154.2M+0.2%	$154.0M-0.6%	$154.9M-2.1%	$158.1M+4.1%	$152.0M-1.6%	$154.4M
Current Liabilities	N/A	$645K+7.9%	$598K+72.3%	$347K-64.4%	$975K-41.5%	$1.7M+82.3%	$914K-57.0%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$728K-81.7%	$4.0M+102.7%	-$149.2M-0.9%	-$147.9M-0.5%	-$147.2M+0.5%	-$148.0M-3.5%	-$143.1M-3.6%	-$138.0M
Retained Earnings	-$308.9M-0.5%	-$307.3M+33.3%	-$460.4M-0.3%	-$459.0M-0.2%	-$458.0M-0.3%	-$456.4M-1.1%	-$451.4M-1.3%	-$445.9M

GRTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.0M+50.2%	-$12.1M+72.9%	-$44.8M-3.3%	-$43.4M+36.1%	-$68.0M-14.1%	-$59.5M
Capital Expenditures	N/A	$0-100.0%	$59K+136.0%	$25K-91.2%	$283K-38.1%	$457K
Free Cash Flow	N/A	-$12.1M+73.0%	-$44.9M-3.4%	-$43.5M+36.3%	-$68.2M-13.7%	-$60.0M
Investing Cash Flow	$3.5M+7708.7%	-$46K-100.2%	$27.3M+13.7%	$24.0M+358.1%	$5.2M-85.7%	$36.5M
Financing Cash Flow	$635K-71.4%	$2.2M-92.9%	$31.5M+709.9%	$3.9M-94.2%	$66.7M+225.3%	$20.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$875K+45.2%	-$1.6M-111.1%	-$757K+48.0%	-$1.5M+34.9%	-$2.2M+4.3%	-$2.3M-1.8%	-$2.3M+15.4%	-$2.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$2.3M-1.8%	-$2.3M	N/A
Investing Cash Flow	N/A	$3.5M	N/A	N/A	N/A	-$50K-1350.0%	$4K	$0
Financing Cash Flow	$0	$0	$0	$0-100.0%	$635K-71.4%	$2.2M	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GRTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-1213.1%
Return on Assets	N/A	-187.7%+38.3pp	-226.0%-84.7pp	-141.3%-44.6pp	-96.7%-8.4pp	-88.3%
Current Ratio	11.00+5.0	6.00+1.6	4.36+1.5	2.88-3.1	5.98+0.4	5.58
Debt-to-Equity	0.81+1.9	-1.07+0.1	-1.20+0.2	-1.40+1.0	-2.44-15.2	12.75
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-220.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-26.1%	N/A	-27.8%-10.0pp	-17.8%+3.0pp	-20.8%	N/A	-62.7%-37.9pp	-24.8%
Current Ratio	N/A	11.00+2.8	8.20-8.9	17.14+9.4	7.75+1.8	6.00-3.7	9.74+4.1	5.63
Debt-to-Equity	7.47+6.7	0.81+1.8	-1.030.0	-1.04+0.0	-1.05+0.0	-1.070.0	-1.06+0.1	-1.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ocean Biomedical Inc. OCEA

$6.8M

Vaccinex Inc VCNX

$2.8M

Ayala Pharm ADXS

$25.7M

Axim Biotechnologies Inc AXIM

$1.7M

Regen Biopharma RGBPP

Frequently Asked Questions

What is Galera Therapeutics, Inc.'s EBITDA?

Galera Therapeutics, Inc. (GRTX) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Galera Therapeutics, Inc.'s operating cash flow?

Galera Therapeutics, Inc. (GRTX) generated -$6.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Galera Therapeutics, Inc.'s total assets?

Galera Therapeutics, Inc. (GRTX) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Galera Therapeutics, Inc. spend on research and development?

Galera Therapeutics, Inc. (GRTX) invested $349K in research and development during fiscal year 2025.

How many shares does Galera Therapeutics, Inc. have outstanding?

Galera Therapeutics, Inc. (GRTX) had 75M shares outstanding as of fiscal year 2025.

What is Galera Therapeutics, Inc.'s current ratio?

Galera Therapeutics, Inc. (GRTX) had a current ratio of 11.00 as of fiscal year 2025, which is generally considered healthy.

What is Galera Therapeutics, Inc.'s debt-to-equity ratio?

Galera Therapeutics, Inc. (GRTX) had a debt-to-equity ratio of 0.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Galera Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Galera Therapeutics, Inc. (GRTX) had $6.4M in cash against an annual operating cash burn of $6.0M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

How financially healthy is Galera Therapeutics, Inc.?

Galera Therapeutics, Inc. (GRTX) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.